Search research articles
Contact Us
Filters
Showing results (321-330 of 332) with videos related to
Page
of 34
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 23, 2006
Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study
Hervé Rubie, Julia Chisholm, Anne Sophie Defachelles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2009
Overall genomic pattern is a predictor of outcome in neuroblastoma
Isabelle Janoueix-Lerosey, Gudrun Schleiermacher, Evi Michels, et al.
British Journal of Cancer
|
October 8, 2024
Role of <sup>18</sup>F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?
Nina Jehanno, Nadège Corradini, Nathalie Gaspar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2010
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1
Hervé Rubie, Bruno De Bernardi, Mary Gerrard, et al.
British Journal of Cancer
|
September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
G Schleiermacher, V Mosseri, W B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial
Birgitta Lannering, Stefan Rutkowski, Francois Doz, et al.
Oncoimmunology
|
September 14, 2016
Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma
Maude Guillot-Delost, Lia Guilleré, Frédérique Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2011
Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor
Franck Bourdeaut, Delphine Lequin, Laurence Brugières, et al.
Pediatric Blood & Cancer
|
September 4, 2025
Atypical Neuroblastoma With Absent Urinary Catecholamine Excretion and <sup>123</sup>ImIBG Avidity Are of Favorable Outcome: A Retrospective French Single-Center Study
Anna Borovkov, Juliette Assy, Isabelle Aerts, et al.
British Journal of Cancer
|
December 8, 2011
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
G Schleiermacher, J Michon, A Ribeiro, et al.
Page
of 34
Search research articles
Search
Showing results (321-330 of 332) with videos related to
Sort By:
Page
of 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 23, 2006
Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study
Hervé Rubie, Julia Chisholm, Anne Sophie Defachelles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2009
Overall genomic pattern is a predictor of outcome in neuroblastoma
Isabelle Janoueix-Lerosey, Gudrun Schleiermacher, Evi Michels, et al.
British Journal of Cancer
|
October 8, 2024
Role of <sup>18</sup>F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?
Nina Jehanno, Nadège Corradini, Nathalie Gaspar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2010
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1
Hervé Rubie, Bruno De Bernardi, Mary Gerrard, et al.
British Journal of Cancer
|
September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project
G Schleiermacher, V Mosseri, W B London, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial
Birgitta Lannering, Stefan Rutkowski, Francois Doz, et al.
Oncoimmunology
|
September 14, 2016
Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma
Maude Guillot-Delost, Lia Guilleré, Frédérique Berger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2011
Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor
Franck Bourdeaut, Delphine Lequin, Laurence Brugières, et al.
Pediatric Blood & Cancer
|
September 4, 2025
Atypical Neuroblastoma With Absent Urinary Catecholamine Excretion and <sup>123</sup>ImIBG Avidity Are of Favorable Outcome: A Retrospective French Single-Center Study
Anna Borovkov, Juliette Assy, Isabelle Aerts, et al.
British Journal of Cancer
|
December 8, 2011
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
G Schleiermacher, J Michon, A Ribeiro, et al.
Page
of 34